METABOLIC MEASUREMENT AND MONITORING IN CLINICAL HYPERTHERMIA

该项目成功地研究了磁共振成像（MRI）， 31 P波谱（MRS）用于评估预后和监测治疗结果 在接受以下治疗的患有软组织肉瘤的人类和犬患者中， 联合热疗（HT）和放射治疗（RT）。有强有力 基本原理是在定义的 一组肿瘤，无论是在未扰动状态和治疗后 干预以提高我们对生理机制的理解 对热放疗的临床反应。这种生理代谢 数据可以极大地帮助开发和部署反 肿瘤治疗，特别是如果这些信息可以被证明是 独立于其他已知的预后变量。 具体来说，我们需要能够（l）在治疗之前识别出那些 最有可能从特定疗程中获益的患者，（2） 在治疗过程的早期识别无反应的患者， 谁的替代疗法可以实施最大的疗效。 这项研究的目的是继续评估肿瘤的有用性， 通过31 P MRS、1H MR 1、Eppendorf pO 2评估的生理特征 组织图和电极pHe测量作为评估方法 癌症患者的预后和监测治疗。重要的是 这是在对照良好的研究中进行的， 方案和明确定义的临床终点。我们希望评估 先前开发的模型，MRS/MRI推导出治疗前和治疗后 STS的代谢特征也是HT/RT联合治疗的预后因素 作为评估多个参数代谢谱的指标， 治疗预后我们还将评估这些参数是否 对于“可加热的”和“不可加热的”肿瘤， 治疗方案 预测个体患者治疗反应的益处 源自这样一个概念，即可以向无应答者提供 替代疗法，如果存在这种疗法。这样的好处很难 夸大了患者发病率和成本。有 除了直接节省费用外，还有非常重要的好处：（l）不经处理 患者将免于发病率，时间和无效的压力 （2）癌症转移的机会减少 在无效治疗期间;和（3）可替代治疗， 在病人的治疗过程中尝试过。

This project has successfully studied magnetic resonance imaging (MRI) and 31P spectroscopy (MRS) to assess prognosis and monitor therapeutic results in human and canine patients with soft tissue sarcomas treated with combined hyperthermia (HT) and radiation therapy (RT). There is strong rationale to look for correlated profiles of physiologic data in a defined group of tumors, both in the unperturbed state and after therapeutic intervention to improve our understanding of the physiological mechanisms of clinical response to thermoradiotherapy. Such physiologic metabolic data could greatly assist in the development and deployment of anti- neoplastic therapy, especially if this information can be shown to be independent of other known prognostic variables. Specifically, we need to be able (l) to identify, prior to therapy, those patients most likely to benefit from a specific course of therapy, (2) to identify, early during the course of therapy, nonresponding patients for whom therapy alternatives can be implemented with the greatest efficacy. The goal of this study is to continue to evaluate the usefulness of tumor physiologic profiles, as assessed by 31P MRS, 1H MRl, Eppendorf pO2 histographs, and electrode pHe measurements as methods of assessing prognosis and monitoring therapy in cancer patients. It is important that this be done in well controlled studies with clearly specified therapeutic protocols and well defined clinical endpoints. We expect to evaluate the prior developed model that MRS/MRI derived pretherapy and posttherapy metabolic characteristics of STS are prognostic for combined HT/RT as well as evaluate multiple parameter metabolic profiles as indices of therapeutic prognosis. We also will evaluate whether these parameters are consistent for "heatable" and "non-heatable" tumors in the context of the therapy protocol. The benefits of predicting therapeutic response in individual patients derive from the concept that non-responders could be offered an alternative therapy if such a therapy exists. Such benefits are hard to overstate both in terms of patient morbidity and dollar costs. There are also very important benefits beyond direct cost savings: (l) non-treated patients would be spared morbidity, time, and stress of ineffective treatment; (2) the cancer would have less opportunity to metastasize during an ineffectual treatment; and (3) alternate treatments could be tried earlier in the patient's therapy course.